skip to Main Content

Mark Conway

Tell us about yourself

My name is Mark Conway. I am currently studying Bachelor of Science with concurrent Teacher Education in the University of Limerick. My subject specialisms are Physical Sciences with Chemistry and Physics. I have a fascination with the workings of the world and would like to gain more experience in the scientific community

I applied to the STInt Programme because...

I applied for the STInt Programme as I would like to gain a greater understanding of the processes involved in scientific research as the experience would be valuable for teaching. My fourth year project is about motivating students to take on science subjects as a leaving certificate subject, so having an insight into this area would help in motivating the students to pursue a career in this field.

STInt host

BioMarin is a global biotechnology company dedicated to transforming lives through genetic discovery. In 1997, the company was founded to make a big difference in small patient populations, focusing on giving much-needed attention to the underserved communities of those with rare diseases. BioMarin sought to help patients whose voices could not always be heard and treat conditions that were not always in mainstream medical conversations. Throughout its history, BioMarin has worked tirelessly to make a difference by pursuing bold science. The company’s first approved therapy was inspired by a father who refused to accept there was no therapy for his son’s rare diagnosis. That relentless pursuit to change the course of his son’s future through the power of science is at the core of who BioMarin is today. Through the company’s expertise in genetics and molecular biology, BioMarin has developed eight first or best-in-class targeted therapies that address the root cause of the conditions it seeks to treat, helping to better the lives of those struggling with rare genetic disease. The company’s purposeful and scientifically precise team of physicians and scientists has honed each treatment modality to seek transformative therapies.  Now, BioMarin seeks to make an even greater impact by applying the same science-driven, patient-forward approach that propelled the last 25 plus years of drug development to larger genetic disorders, as well as genetic subsets of more common conditions. Each drug candidate pursued is guided by a fundamental understanding of the genetics and underlying biology of the condition it will address. The company believes that applying its knowledge to make a transformative impact is not just a calling, but an obligation to those who will benefit most. The more innovative solutions developed, the more lives BioMarin can impact.

Mark Conway
Back To Top